Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment.
Attention-deficit hyperactivity disorder (ADHD) and substance-use disorders are related to each other in a variety of ways. Although within the child-psychiatry literature earlier investigations were inconsistent regarding such a link, recent prospective studies that followed hyperactive children and normal controls into adulthood have found that hyperactive adults with a history of ADHD are more likely than controls to have substance-use disorders. The substance-abuse literature is less consistent regarding the potential association between ADHD and substance abuse. However, recent studies suggest that persons with a substance-use disorder, and particularly those with a cocaine-use disorder, may be more likely than the general population to have a childhood history of ADHD. Some of the inconsistency regarding this association is due to differences in diagnostic criteria, type of assessments used, and reliability of information obtained. Each of the potential relationships that may exist between ADHD and substance abuse has treatment implications for the clinician. Pharmacological as well as nonpharmacological approaches deserve further investigation. Because pharmacotherapy is a central component in the treatment of childhood ADHD, clinicians designing a strategy to treat both a substance-use disorder and ADHD need to consider pharmacological interventions. At present, the literature on pharmacological treatment for childhood ADHD is extensive and that for adult ADHD is growing; information regarding the treatment of cocaine abuse and concomitant ADHD symptoms remains limited.
Levin
F R
FR
Department of Psychiatry, Columbia University, New York, N.Y., USA.
Kleber
H D
HD
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000150:complications* / Q000188:drug therapy*; D002675:Child, Preschool; D019970:Cocaine-Related Disorders / Q000188:drug therapy; D003131:Combined Modality Therapy; D006801:Humans; D008774:Methylphenidate / Q000627:therapeutic use*; D011613:Psychotherapy; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D019966:Substance-Related Disorders / Q000150:complications* / Q000188:drug therapy*
D011619:Psychotropic Drugs; D008774:Methylphenidate